The FDA placed BPC-157 in 503A Category 2 in 2023, which blocked compounding pharmacies from preparing it
However, these findings relate to the investigational drug candidate studied under controlled clinical conditions and do not constitute safety or dosing guidance for this research product
Everyone responds to weight loss medications differently, and theres no single timeline that applies to everyone
Nishikawa, M., Tamada, A., Kumai, H., Yamashita, F
December 2023: According to a Reuters report, a Louisiana judge rejected Novo Nordisk's bid to dismiss Bjorklund's claim in August 2023, as the plaintiff had shown enough evidence to support her claim